Volume 27, Number 5—May 2021
Clinical Laboratory Perspective on Streptococcus halichoeri, an Unusual Nonhemolytic, Lancefield Group B Streptococcus Causing Human Infections
|Antimicrobial agent||MIC values, µg/mL
|CLI||77.3||≤0.03 to ≥4||0.03||≥4|
|ERY||72.7||≤0.12 to ≥8||0.12||2|
|Q/D‡||94.7||≤0.25 to ≥4||0.25||0.25|
*CLI, clindamycin; CRO, ceftriaxone; DAP, daptomycin; DOX, doxycycline; ERY, erythromycin; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIC50, MIC value at which ≥50% of the isolates in a test population are inhibited; MIC90, MIC value at which ≥90% of the isolates in a test population are inhibited; NA, not available; PEN, penicillin; Q/D, quinupristin/dalfopristin; VAN, vancomycin. †Clinical and Laboratory Standards Institute interpretive breakpoints for doxycycline were not available for viridans group Streptococcus spp. If breakpoints for S. pneumoniae were applied, 82% would be susceptible (5). ‡n = 19 isolates.
1These authors contributed equally to this article.